{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:49:52Z","timestamp":1761598192388,"version":"3.40.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tumor-associated macrophages (TAM) are pivotal in remodeling of the tumor immune microenvironment and clinical outcome. Herein, we aim to evaluate the impact of immunohistochemical (IHC) expression of CD68 and CD163 in TAM on clinico-pathological features, patients\u2019 response to therapy and the overall survival (OS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This retrospective study was performed on paraffin-embedded tissue blocks of 100 classic Hodgkin Lymphoma (cHL) cases diagnosed and treated at our Institution. Immunohistochemical scores of CD68 and CD163 were statistically related to bulky disease (<jats:italic>p<\/jats:italic> value = 0.005 for both), tumor stage (<jats:italic>p<\/jats:italic> value = 0.02 for both), International Prognostic Score (IPS) (<jats:italic>p<\/jats:italic> value = 0.04 and 0.02 respectively), and the overall response rate (ORR) (<jats:italic>p<\/jats:italic> value = 0.001). Additionally, CD163 was also statistically related to gender (<jats:italic>p<\/jats:italic> value = 0.02), serum albumin level (<jats:italic>p<\/jats:italic> value = 0.03), and B symptoms (<jats:italic>p<\/jats:italic> value = 0.04). HCV seropositivity did not relate to either CD68 or CD163 score. Using univariate analysis revealed that B symptoms, bulky disease, IPS \u2265 3, and CD163 &gt; 25% were associated with lower OS (<jats:italic>p<\/jats:italic> values = 0.003, 0.006, 0.001, and &lt; 0.001 respectively), while after multivariate cox regression analysis, B symptoms, IPS \u2265 3, and CD163 &gt; 25% were related to inferior OS (<jats:italic>p<\/jats:italic> values 0.02, 0.02, and 0.003).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>CD163 expressing TAM is a powerful predictor for OS in cHL, unlike CD68.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43046-020-00029-1","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T16:03:52Z","timestamp":1586966632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinico-pathological significance of immunohistochemically marked tumor-associated macrophage in classic Hodgkin lymphoma"],"prefix":"10.1186","volume":"32","author":[{"given":"Mona Y. Y.","family":"Abd Allah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2685-1220","authenticated-orcid":false,"given":"Maryan Waheeb","family":"Fahmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaimaa","family":"EL-Ashwah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"issue":"1","key":"29_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7\u201330.","journal-title":"CA Cancer J Clin."},{"issue":"Suppl 4","key":"29_CR2","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","volume":"29","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer DA, Aleman BMP, Andr\u00e9 M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; Oct 1;29(Suppl 4):iv19\u201329. https:\/\/doi.org\/10.1093\/annonc\/mdy080.","journal-title":"Ann Oncol"},{"key":"29_CR3","doi-asserted-by":"publisher","first-page":"437971","DOI":"10.1155\/2014\/437971","volume":"2014","author":"AS Ibrahim","year":"2014","unstructured":"Ibrahim AS, Khaled HM, Mikhail NNH, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. https:\/\/doi.org\/10.1155\/2014\/437971 Epub 2014 Sep 21.","journal-title":"J Cancer Epidemiol."},{"issue":"8","key":"29_CR4","first-page":"518","volume":"13","author":"F Montanari","year":"2015","unstructured":"Montanari F, Diefenbach CS. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy. Clin Adv Hematol Oncol. 2015;13(8):518\u201324.","journal-title":"Clin Adv Hematol Oncol."},{"issue":"18","key":"29_CR5","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1182\/bloodadvances.2017006346","volume":"1","author":"P Hollander","year":"2017","unstructured":"Hollander P, Kamper P, Smedby KE, Enblad G, Ludvigsen M, Mortensen J, et al. High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome. Blood Adv. 2017;1(18):1427\u201339.","journal-title":"Blood Adv."},{"issue":"1","key":"29_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/ejh.12987","volume":"100","author":"P Hollander","year":"2018","unstructured":"Hollander P, Rostgaard K, Smedby KE, Molin D, Loskog A, de Nully BP, et al. An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome. Eur J Haematol. 2018;100(1):88\u201397.","journal-title":"Eur J Haematol."},{"issue":"4","key":"29_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/gm240","volume":"3","author":"E Derenzini","year":"2011","unstructured":"Derenzini E, Younes A. Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. Genome Med. 2011;3(4):26.","journal-title":"Genome Med."},{"issue":"10","key":"29_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMe0912481","volume":"362","author":"VT DeVita Jr","year":"2010","unstructured":"DeVita VT Jr, Costa J. Toward a personalized treatment of Hodgkin\u2019s disease. N Engl J Med. 2010 Mar 11;362(10):942\u20133. https:\/\/doi.org\/10.1056\/NEJMe0912481.","journal-title":"N Engl J Med."},{"issue":"1","key":"29_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12916-016-0711-6","volume":"14","author":"B Guo","year":"2016","unstructured":"Guo B, Cen H, Tan X, Ke Q. Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma. BMC Med. 2016 Oct 17;14(1):159.","journal-title":"BMC Med."},{"issue":"3","key":"29_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/annonc\/mdr157","volume":"23","author":"D Azambuja","year":"2012","unstructured":"Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin\u2019s lymphoma. Ann Oncol. 2012;23(3):736\u201342.","journal-title":"Ann Oncol."},{"issue":"21","key":"29_CR11","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V, Armitage JO, Assouline D, Bj\u00f6rkholm M, Brusamolino E, et al. A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506\u201314. https:\/\/doi.org\/10.1056\/NEJM199811193392104.","journal-title":"N Engl J Med."},{"key":"29_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1746-1596-7-12","volume":"7","author":"JA Harris","year":"2012","unstructured":"Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol. 2012 Jan 30;7:12. https:\/\/doi.org\/10.1186\/1746-1596-7-12.","journal-title":"Diagn Pathol."},{"key":"29_CR13","first-page":"9720912","volume":"2016","author":"Q Guo","year":"2016","unstructured":"Guo Q, Jin Z, Yuan Y, Liu R, Xu T, Wei H, et al. New mechanisms of tumor-associated macrophages on promoting tumor progression: recent research advances and potential targets for tumor immunotherapy. J Immunol Res. 2016;2016:9720912 Epub 2016 Nov 16.","journal-title":"J Immunol Res."},{"issue":"2","key":"29_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/0192623311430695","volume":"40","author":"JE Rehg","year":"2012","unstructured":"Rehg JE, Bush D, Ward JM. The utility of immunohistochemistry for the identification of hematopoietic and lymphoid cells in normal tissues and interpretation of proliferative and inflammatory lesions of mice and rats. Toxicol Pathol. 2012;40(2):345\u201374.","journal-title":"Toxicol Pathol."},{"issue":"6","key":"29_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883\u201399.","journal-title":"Cell."},{"issue":"1","key":"29_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","volume":"10","author":"L Yang","year":"2017","unstructured":"Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):58.","journal-title":"J Hematol Oncol."},{"issue":"1","key":"29_CR17","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/asheducation-2013.1.584","volume":"2013","author":"WH Wilson","year":"2013","unstructured":"Wilson WH. Treatment strategies for aggressive lymphomas: what works? Hematology Am Soc Hematol Educ Program. 2013;2013(1):584\u201390.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"29_CR18","doi-asserted-by":"publisher","unstructured":"Weichselbaum RR, Liang H, Deng L, Fu Y-X. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365-379. doi: https:\/\/doi.org\/10.1038\/nrclinonc.2016.211. Epub 2017 Jan 17.","DOI":"10.1038\/nrclinonc.2016.211"},{"issue":"3","key":"29_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1309\/AJCP61TLMXLSLJYS","volume":"141","author":"JL Klein","year":"2014","unstructured":"Klein JL, Nguyen TT, Bien-Willner GA, Chen L, Foyil KV, Bartlett NL, et al. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am J Clin Pathol. 2014;141(3):381\u20137.","journal-title":"Am J Clin Pathol."}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-020-00029-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-020-00029-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-020-00029-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T23:15:27Z","timestamp":1618442127000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-020-00029-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["29"],"URL":"https:\/\/doi.org\/10.1186\/s43046-020-00029-1","relation":{},"ISSN":["2589-0409"],"issn-type":[{"type":"electronic","value":"2589-0409"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"7 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The current study was reviewed and approved by the Institutional review board (IRB) of Faculty of Medicine, Mansoura University (Code number: R\/18.02.27).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}